Aeronid^? is a preperation of Budesonide,which is a glucocorticoid steroid that have potent anti-inflammatory actions that reduces inflammation and hyper-reactivity (spasm) of the airways caused by asthma. When used as an inhaler, the budesonide goes directly to the inner lining of the inflamed airways to exert its effects. Aeronoid is safe to be used in pregnancy & for children.

Azmasol^?, is a short-acting bronchodilator which keeps the bronchial tubes in the lungs open and relieves the symptoms of asthma and other chest conditions.Azmasol^? is useful as the treatment of activity-induced bronchospasm in asthma attacks & COPD.

Azmasol® (Salbutamol Sulphate BP) is a synthetic sympathomimetic agent with predominant beta-adrenergic activity and selective action on receptors of bronchial muscle. It is used for the treatment of reversible obstruction of the airway.

Azmasol® Respirator Solution is an aqueous solution of Salbutamol Sulphate BP. Salbutamol is one of a group of medicines called bronchodilators or 'relievers' and it is a ?2- adrenoceptor agonist, used in the treatment of asthma and other forms of diffuse reversible airways obstruction.

Azmasol^? HFA inhaler is an environment friendly, CFC-free inhaler. It contains Salbutamol BP (as sulfate) as the active ingredient which is a ?2- adrenoceptor agonist used in the treatment of asthma and other forms of diffuse reversible airways obstruction. It is indicated for the treatment and prophylaxis of bronchial asthma and for the treatment of reversible airways obstruction associated with bronchitis and emphysema. it is also (Salbutamol) inhaler may be used to relieve attacks of acute dyspnoea and be taken prophylactically before exertion or to prevent exercise-induced asthma

Bexitrol inhaler is a preperation of Salmeterol which is a long acting beta 2 agonist and bronchodilator (inhalation) medication commonly used to prevent and treat the symptoms in people with mild to moderate asthma.long acting beta -2 agonist helps in the prevention of nocturnal asthma attack

Salmeterol Xinafoate BP, the active ingredient of Bexitrol® Inhaler, is a selective, long acting ß2-agonist used in the treatment of asthma and other forms of diffuse airways obstruction. Bexitrol® Inhaler is a metered dose aerosol unit containing a micro-crystalline suspension of Salmeterol Xinafoate in a mixture of Dehydrated Alcohol (Ethanol), Oleic Acid & Propellant (HFA 134a).

Salmeterol Xinafoate is a selective, long acting b2 agonist used in the treatment of asthma and other forms of diffuse airways obstruction. Fluticasone Propionate is a corticosteroid with mainly glucocorticoid activity. Fluticasone Propionate is stated to exert a topical effect on the lungs without systemic effects at usual dose. Bexitrol-F combines both ingredients in single inhaler. Bexitrol F is indicated in the regular treatment of asthma where use of a combination product (long acting b2 agonist and inhaled corticosteroid) is appropriate: 1. Patients not adequately controlled with inhaled corticosteroids and with "as needed" inhaled short acting b2 agonist or 2. Patients already adequately controlled on both inhaled corticosteroids and long acting b2 agonist.

Bexitrol®-F metered dose inhaler is a combination of Salmeterol Xinafoate BP and Fluticasone Propionate BP. Salmeterol Xinafoate is a selective, long acting beta-2 agonist used in the treatment of asthma and other forms of diffuse airways obstruction. Fluticasone Propionate is a corticosteroid with mainly glucocorticoid activity. Fluticasone Propionate is stated to exert a topical effect on the lungs without systematic effects at usual dose.

Bexitrol®-F metered dose inhaler is a combination of Salmeterol Xinafoate BP and Fluticasone Propionate BP. Salmeterol Xinafoate is a selective, long acting beta-2 agonist used in the treatment of asthma and other forms of diffuse airways obstruction. Fluticasone Propionate is a corticosteroid with mainly glucocorticoid activity. Fluticasone Propionate is stated to exert a topical effect on the lungs without systematic effects at usual dose.

Cesonide^? contains ciclesonide is a new generation inhaled corticosteroid for asthma. It is indicated for the treatment to control persistent asthma in adults (18 years and older).

Decomit Inhaler is indicated for wide range of patients with bronchial asthma.Decomit contains Beclomethasone.Beclomethasone is a synthetic corticosteroid and is used to decrease inflammation in the lungs. When inhaled into the lungs it is absorbed into the cells of the lungs and airways. Here it works by preventing the release of certain chemicals from the cells. By preventing the inflammation and excess mucus formation, beclomethasone helps prevent asthma attacks.

Decomit^? HFA is a metered dose inhaler (MDI) contains beclomethasone dipropionate. It is environment friendly inhaler which contains ozone-benign propellant replacing CFC propellant. Decomit HFA is indicated in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older. Beclomethasone dipropionate is also indicated for asthma patients who require systemic corticosteroid administration, where adding Beclomethasone dipropionate may reduce or eliminate the need for the systemic corticosteroids.

Ipramid is a preperation of Ipratropium bromide which is a anticholinergic agent that works as a bronchodilator that dilates the bronchi in the lungs. It is used in treating chronic obstructive pulmonary disease associated with chronic bronchitis and emphysema. In chronic obstructive pulmonary disease, cholinergic nerves going to the lungs cause narrowing of the bronchi by stimulating the muscles surrounding the bronchi to contract. An "anti-cholinergic" effect of ipratropium bromide blocks the effect of the cholinergic nerves, causing the muscles to relax and the bronchi to dilate.

Ipratropium bromide is an anticholinergic bronchodilator. It inhibits vagally mediated reflexes by antagonizing, the action of acetylcholine, the transmitter agent released from the vagal nerve.

Iprasol is a preperation of Salbutamol & Ipratropium bromide.Salbutamol is a beta2-adrenergic agent which acts on airway smooth muscle resulting in relaxation. Ipratropium Bromide is a anticholinergic agent that works as a bronchodilator that dilates the bronchi in the lungs. Iprasol provides the simultaneous release of ipratropium bromide and salbutamol allowing the synergistic efficacy on the muscarinic and beta2-adrenergic receptors in the airways to cause bronchodilation which is superior to that provided by each single agent and with no potentiation of adverse events.

This Inhalation Solution is a combination of the anticholinergic bronchodilator, ipratropium bromide, and the ß2-adrenergic bronchodilator, salbutamol sulfate. Ipratropium bromide is a quaternary ammonium derivative of atropine and is an anticholinergic drug which has bronchodilator properties. On inhalation, the onset of action is noted within 5 to 15 minutes, with a peak response between 1 and 2 hours, lasting about 2 additional hours, with subsequent decline from the peak. Bronchodilation is still evident 8 hours after inhalation. Salbutamol produces bronchodilation through stimulation of ß2-adrenergic receptors in bronchial smooth muscle, thereby causing relaxation of muscle fibres. This action is manifested by an increase in pulmonary function as demonstrated by spirometric measurements. A measurable decrease in airway resistance is typically observed 5 to 15 minutes after inhalation of salbutamol. The maximum improvement in pulmonary function usually occurs after 60 to 90 minutes, and significant bronchodilator activity has been observed to persist from 3 to 6 hours.

Monocast is indicated for the prophylaxis and chronic treatment of asthma in adults and paediatric patients 12 months of age and older. Monocast is indicated for the relief of symptoms of seasonal allergic rhinitis in adults and paediatric patients 2 years of age and older.

Oxymetazoline Hydrochloride, the active ingredient of Nazolin^? nasal spray, is a sympathomimetic amine of the imidazoline class. Nazolin^? is indicated for the following purposes as a nasal decongestant in allergic rhinitis, with or without the addition of topical antihistamines or sodium cromoglycate; as a nasal decongestant in sinusitis where there is evidence of obstruction of ostea to the sinuses; as nasal decongestant in otitis media where there is evidence of obstruction of eustachian tube, especially in subacute serous otitis media (?glue ear?) and otitic barotrauma; as a decongestant in an infective rhinitis(e.g. an acute viral upper respiratory tract infection). where there is a secondary bacterial infection, there is no evidence of benefit.

Perinase^? nasal spray is an aqueous suspension of microfine Fluticasone Propionate for topical administration to the nasal mucosa by means of a metering, atomizing spray pump. The active ingredient Fluticasone Propionate is a synthetic corticosteroid.Perinase^? nasal spray is indicated for the management of the nasal symptoms of seasonal and perennial allergic and nonallergic rhinitis in adults and pediatric patients 4 years of age and older.

Respira^? is a preparation of Levosulbutamol sulphate. It is a beta 2 agonist and indicated for the treatment or prevention of bronchospasm in adults, adolescents and children 4 years of age and older with reversible obstructive airway disease.

Tofen^? is a preparation of Ketotifen which has antiallergic & anti-anaphylactic properties is used in the prophylactic treatment of bronchial asthma & symptomatic treatment of allergic conditions including rhinitis & conjunctivitis.The prophylactic activity of Tofen^? may take several weeks to become fully established. Tofen^? will not abort established attacks of asthma.

Triomid^? which is a preparation of Tiotropium Bromide is the first and only inhaled COPD agent that offers 24 hours bronchodilation with once-daily dosing. It is indicated for the long-term, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

Zukast (Zafirlukast) is a synthetic, selective peptide leukotriene receptor antagonist (LTRA) that acts as a prophylactic agent against inflammation in asthma & is indicated for the treatment of asthma.Zukast should be taken continuously.